

# NCI SBIR AND YOUR STATE:

## WASHINGTON



Between FY1998 and FY2010, the NCI SBIR Development Center awarded **\$46.1 million** in funding across **44 Phase II SBIR/STTR grants** to small businesses in Washington. The following economic impact estimates quantify the program's contributions to the state's economy:



**\$425.5M**

**IN TOTAL DIRECT SALES**



**\$974M**

**IN TOTAL ECONOMIC IMPACT**



**4.7K**

**JOBS CREATED**



**\$36M**

**IN STATE & LOCAL TAXES COLLECTED**



**18**

**COMPANIES WITH SALES**

*\*These state-specific figures are derived from the 2018 NCI SBIR/STTR Economic Impact Study analysis, which assessed the impact of Phase II grant awards initiated from FY1998-FY2010 and the economic results of these investments up to 2018. NCI continues to provide SBIR/STTR grant awards in Washington: between FY1998 and FY2024, the NCI SBIR Development Center distributed \$121.9M in funding across all grants to oncology-focused small businesses in the state.*

### Success stories include: **TRANSPIRE, INC.**

SBIR funds supported the development of Transpire's FDA-cleared Acuros, a dose calculation software for enhancing radiation therapy dose accuracy to achieve more effective and safer cancer treatments. In 2014, Varian Medical System acquired the technology and it has since been integrated into the company's treatment planning software products.

### **ADAPTIVE BIOTECHNOLOGIES CORPORATION**

Adaptive Biotechnologies used SBIR funding to develop a deep sequencing assay and diagnostic protocol for evaluating how effectively a cancer patient responds to ipilimumab, a monoclonal antibody that stimulates the body's immune response to cancer cells. The company went public in June 2019, raising \$345 million in its IPO.

**The NCI SBIR Development Center offers information sessions on funding opportunities and resources for cancer technology startups. If your state is interested in hosting, please reach out to [ncisbir@mail.nih.gov](mailto:ncisbir@mail.nih.gov).**